

NOW APPROVED FOR THALASSEMIA



Transforming Thalassemia Treatment With AQVESME™

PROGRAM OVERVIEW

100 years after the discovery of the disease, discover how **AQVESME** can change the thalassemia treatment paradigm. This program will review the efficacy and safety profile of **AQVESME** in adults, the **ONLY** treatment for anemia in **BOTH** non-transfusion-dependent (**NTD**) and transfusion-dependent (**TD**), **α**- or **β**-thalassemia.

3 Options to Attend Virtually

Virtual Option 1

Tuesday, January 27, 2026

Start Time:
6:30 PM Eastern Time

PRESENTED BY:

Alexander Glaros, MD
Clinical Trial Investigator,
Pediatric Hematologist-Oncologist
Children's Hospital of
Michigan
Detroit, Michigan

INVITE CODE: **CJXURY**

Virtual Option 2

Wednesday, January 28, 2026

Start Time:
6:30 PM Central Time

PRESENTED BY:

Sherif Badawy, MD, MS, MBA
Director, Comprehensive
Thalassemia Program
Ann and Robert H. Lurie
Children's Hospital
Chicago, Illinois

INVITE CODE: **DWUB7U**

Virtual Option 3

Thursday, January 29, 2026

Start Time:
6:30 PM Pacific Time

PRESENTED BY:

Sherif Badawy, MD, MS, MBA
Director, Comprehensive
Thalassemia Program
Ann and Robert H. Lurie
Children's Hospital
Chicago, Illinois

INVITE CODE: **DW6KHE**

Faculty are paid speakers presenting on behalf of Agios Pharmaceuticals, Inc.

See Attendee and Reporting Policy on next page.



Scan the QR Code to Register Now!

Log-in details for your selected option will be provided following registration.
Enter the applicable invite code provided above to register for your preferred option.

α, alpha; β, beta.

INDICATION

AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: HEPATOCELLULAR INJURY

AQVESME can cause serious hepatocellular injury. Measure liver laboratory tests (ALT, AST, alkaline phosphatase and total bilirubin with fractionation) at baseline and every 4 weeks for 24 weeks and then as clinically indicated. Avoid use of AQVESME in patients with cirrhosis. Discontinue AQVESME if hepatic injury is suspected.

Because of the risk of hepatocellular injury, AQVESME is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AQVESME REMS.

Please see additional Important Safety Information on next page and accompanying Full Prescribing Information for AQVESME, including Boxed Warning.